STAT Plus: A compounder loses a battle with the FDA over using bulk substances
APSTOCK
At issue was a dispute over whether a compounded drug filled a legitimate clinical need and should remain on the market alongside a brand-name version.
Suscribirse a:
Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario